{"id":"parenteral-insulin","safety":{"commonSideEffects":[{"rate":"variable, dose-dependent","effect":"Hypoglycemia"},{"rate":"common","effect":"Weight gain"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"variable","effect":"Lipodystrophy"},{"rate":"<1","effect":"Allergic reactions"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin is a hormone that binds to insulin receptors on cell surfaces, facilitating glucose transport into muscle, fat, and liver cells. This reduces blood glucose levels and promotes anabolic metabolism. Parenteral (injected) insulin is used when the pancreas cannot produce sufficient endogenous insulin, as in type 1 diabetes or advanced type 2 diabetes.","oneSentence":"Parenteral insulin replaces or supplements the body's own insulin to regulate blood glucose by promoting glucose uptake into cells and storage as glycogen.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:37.938Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus (when oral agents are insufficient)"}]},"trialDetails":[{"nctId":"NCT07446998","phase":"PHASE2","title":"Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss","status":"RECRUITING","sponsor":"Veru Inc.","startDate":"2026-03","conditions":"Obesity & Overweight, Mobility Disability, HOMA-IR","enrollment":200},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT06140147","phase":"NA","title":"Protocolized Reduction of Non-resuscitation Fluids Versus Usual Care in Septic Shock Patients","status":"RECRUITING","sponsor":"Region Skane","startDate":"2023-11-27","conditions":"Septic Shock","enrollment":1850},{"nctId":"NCT06904846","phase":"NA","title":"To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period","status":"ENROLLING_BY_INVITATION","sponsor":"Sinocare","startDate":"2025-04-23","conditions":"Diabetes Mellitus, Continuous Glucose Monitoring System","enrollment":70},{"nctId":"NCT06445946","phase":"PHASE4","title":"DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-08-01","conditions":"Gestational Diabetes Mellitus, Pregnancy, High Risk","enrollment":1572},{"nctId":"NCT07317856","phase":"NA","title":"Efficacy of Microneedling With Hyaluronic Acid Injection for Gingival Augmentation in Thin Gingival Phenotype","status":"NOT_YET_RECRUITING","sponsor":"University of Baghdad","startDate":"2026-01","conditions":"Thin Gingival Biotype","enrollment":20},{"nctId":"NCT07316582","phase":"PHASE4","title":"Melatonin Loaded in Injectable Platelet-Rich Fibrin in the Management Periodontitis","status":"ENROLLING_BY_INVITATION","sponsor":"Al-Azhar University","startDate":"2025-11-01","conditions":"Periodontitis Stage II","enrollment":60},{"nctId":"NCT07255807","phase":"NA","title":"Defining the Human Insulin Resistance Molecular Network; SIGNATURE","status":"NOT_YET_RECRUITING","sponsor":"University of Copenhagen","startDate":"2025-12-01","conditions":"Metabolic Health, Insulin Sensitivity/Resistance","enrollment":80},{"nctId":"NCT07121504","phase":"NA","title":"Hybrid Closed-Loop for Perioperative Glycemic Control in T2DM With Parenteral Nutrition","status":"RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2025-06-26","conditions":"Type 2 Diabetes","enrollment":40},{"nctId":"NCT06968286","phase":"NA","title":"The Effect of Locally Dilvered Ciprofloxacine Loaded Injectable Platelet-rich Fibrin as an Adjunct to Non-surgical Periodontal Therapy on the Gingival Crevicular Level of Interleukin 6","status":"COMPLETED","sponsor":"Suez Canal University","startDate":"2025-01-01","conditions":"Periodontitis Stage II","enrollment":60},{"nctId":"NCT05065372","phase":"PHASE1","title":"MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes","status":"RECRUITING","sponsor":"Kalie Tommerdahl","startDate":"2022-07-01","conditions":"Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases","enrollment":60},{"nctId":"NCT06854861","phase":"PHASE1, PHASE2","title":"Premixed Glucagon/Insulin Solution for Faster Insulin Absorption in Type 1 Diabetes","status":"SUSPENDED","sponsor":"St. Olavs Hospital","startDate":"2025-04-01","conditions":"Type 1 Diabetes","enrollment":30},{"nctId":"NCT05786521","phase":"PHASE4","title":"Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2023-04-01","conditions":"Aging, Diabetes Mellitus, Type 2, PreDiabetes","enrollment":20},{"nctId":"NCT06002048","phase":"","title":"AI Ready and Exploratory Atlas for Diabetes Insights","status":"ENROLLING_BY_INVITATION","sponsor":"University of Washington","startDate":"2023-07-19","conditions":"Type 2 Diabetes","enrollment":4000},{"nctId":"NCT03899402","phase":"PHASE2, PHASE3","title":"Triple Therapy in T1DM","status":"ACTIVE_NOT_RECRUITING","sponsor":"State University of New York at Buffalo","startDate":"2019-05-01","conditions":"Type 1 Diabetes Mellitus","enrollment":78},{"nctId":"NCT02496780","phase":"PHASE2, PHASE3","title":"The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2015-08","conditions":"Cystic Fibrosis","enrollment":65},{"nctId":"NCT06256497","phase":"","title":"A Prospective Study to Evaluate Revita DMR Post Market Pilot Clinical Follow-Up Registry in Patient With Type 2 Diabetes","status":"SUSPENDED","sponsor":"Fractyl Health Inc.","startDate":"2023-06-27","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT05591326","phase":"NA","title":"The Effect of Using Injectable Platelet-rich Fibrin on Root Surface Closure in Patients with Gingival Recession.","status":"ENROLLING_BY_INVITATION","sponsor":"Berceste Guler","startDate":"2021-09-06","conditions":"Gingival Recession, Gingival Recession, Localized","enrollment":50},{"nctId":"NCT06577584","phase":"","title":"Comparison of Diabetes Patients - Care Trajectory Versus Convention","status":"NOT_YET_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2025-02-01","conditions":"Type 2 Diabetes","enrollment":20000},{"nctId":"NCT06650943","phase":"NA","title":"Nursing Intervention in Weight and Metabolic Syndrome Management in First-episode Psychosis (MetaKOP)","status":"RECRUITING","sponsor":"Hospital de Basurto","startDate":"2023-10-25","conditions":"First Episode Psychosis (FEP), Metabolic Syndrome X","enrollment":88},{"nctId":"NCT05689424","phase":"PHASE1","title":"Suppression of Endogenous Glucose Production by Injectable HDV-Insulin Lispro: A Dose Response Study in Human Subjects With Type 1 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-02-01","conditions":"Type 1 Diabetes","enrollment":18},{"nctId":"NCT06605547","phase":"NA","title":"The Effect of I-PRF As An Adjunct to Non-Surgical Periodontal Therapy on Clinical Parameters in Smokers With Periodontitis","status":"COMPLETED","sponsor":"Abant Izzet Baysal University","startDate":"2023-09-04","conditions":"Periodontitis","enrollment":25},{"nctId":"NCT06056167","phase":"NA","title":"Degludec Insulin Use in Critically Ill Patients","status":"COMPLETED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2023-05-17","conditions":"Diabetes Mellitus, Critical Illness, Hyperglycemia","enrollment":155},{"nctId":"NCT06312605","phase":"PHASE4","title":"The Adjunctive Role of Vitamin C on Pigment Recurrence (Randomized Clinical and Histological Trial)","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2023-08-01","conditions":"Gingival Pigmentation","enrollment":24},{"nctId":"NCT05754424","phase":"PHASE1","title":"AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study","status":"COMPLETED","sponsor":"Arecor Limited","startDate":"2023-02-27","conditions":"Diabetes Mellitus, Type 2","enrollment":41},{"nctId":"NCT06236958","phase":"","title":"Effect of Early Enteral Nutrition on Postoperative Recovery of Ovarian Cancer Patients","status":"UNKNOWN","sponsor":"Luo Chengyan","startDate":"2023-12-01","conditions":"Advanced Epithelial Ovarian Cancer","enrollment":200},{"nctId":"NCT01524705","phase":"PHASE4","title":"FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-08","conditions":"Type 2 Diabetes","enrollment":102},{"nctId":"NCT05360537","phase":"PHASE4","title":"Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2021-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT05249088","phase":"NA","title":"Protocolized Reduction of Non-resuscitation Fluids vs Usual Care in Septic Shock Feasibility Trial","status":"COMPLETED","sponsor":"Region Skane","startDate":"2022-03-01","conditions":"Shock, Septic","enrollment":98},{"nctId":"NCT06021301","phase":"PHASE2","title":"Injectable Platelet-Rich Fibrin and Microneedling For Papillae Reconstruction In Esthetic Zone","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-11","conditions":"Injectable Platelet Rich Fibrin and Microneedling in Papilla Reconstruction, Interdental Papillae Reconstruction","enrollment":10},{"nctId":"NCT03258853","phase":"NA","title":"Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-08-26","conditions":"Cystic Fibrosis-related Diabetes","enrollment":22},{"nctId":"NCT03222245","phase":"","title":"The Effect of Injectable Therapies on Quality of Life in Diabetes","status":"COMPLETED","sponsor":"Portsmouth Hospitals NHS Trust","startDate":"2017-06-30","conditions":"Diabetes","enrollment":256},{"nctId":"NCT05786885","phase":"NA","title":"Microneedling With Vitamin C Versus Injectable Vitamin C for Depigmentation in Gingival Melanin Hyperpigmentation","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-04","conditions":"Gingival Pigmentation","enrollment":22},{"nctId":"NCT02102243","phase":"PHASE4","title":"Neural Mechanism of Aldosterone-induced Insulin Resistance","status":"WITHDRAWN","sponsor":"Wanpen Vongpatanasin","startDate":"2010-11","conditions":"Hypertension","enrollment":""},{"nctId":"NCT05112354","phase":"PHASE2","title":"Predictive Factors for Recovery in Idiopathic Sensory Neural Hearing Loss","status":"COMPLETED","sponsor":"Assiut University","startDate":"2019-12-01","conditions":"Idiopathic Sudden SNHL","enrollment":40},{"nctId":"NCT03415061","phase":"NA","title":"Effect of Intranasal Insulin on POCD and POD","status":"UNKNOWN","sponsor":"Hiroaki Sato, MD., PhD.","startDate":"2021-11-01","conditions":"Delirium, Heart Diseases","enrollment":494},{"nctId":"NCT03324867","phase":"NA","title":"The Effect of Intranasal Insulin Administration on Cognitive Function After Cardiac Surgery.","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2022-04","conditions":"Cognitive Decline, Heart Diseases, Delirium","enrollment":316},{"nctId":"NCT01533129","phase":"PHASE4","title":"The Effect of Testosterone Replacement on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Hypogonadotrophic Hypogonadism","status":"COMPLETED","sponsor":"Gulhane School of Medicine","startDate":"2008-08","conditions":"Hypogonadotrophic Hypogonadism","enrollment":106},{"nctId":"NCT00004984","phase":"PHASE3","title":"The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1994-02","conditions":"Diabetes Mellitus, Type 1","enrollment":711},{"nctId":"NCT00821795","phase":"PHASE4","title":"Veterans Inpatient Insulin Study and Transition to Outpatient Therapy","status":"COMPLETED","sponsor":"Dennis G. Karounos, M.D.","startDate":"2009-03-11","conditions":"Type 2 Diabetes Mellitus","enrollment":120},{"nctId":"NCT01892319","phase":"","title":"An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-09-30","conditions":"Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":2446},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT00157339","phase":"PHASE3","title":"Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-08","conditions":"Diabetes Mellitus, Asthma, Pulmonary Disease, Chronic Obstructive","enrollment":299},{"nctId":"NCT00330473","phase":"PHASE3","title":"A Concordance Study Comparing Insulin Treatments in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-06","conditions":"Diabetes Mellitus, Type 2","enrollment":1019},{"nctId":"NCT00355849","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-08","conditions":"Diabetes Mellitus, Type 2","enrollment":555},{"nctId":"NCT00325364","phase":"PHASE3","title":"Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-04","conditions":"Diabetes Mellitus, Type 2","enrollment":415},{"nctId":"NCT00672854","phase":"PHASE2, PHASE3","title":"Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN","status":"COMPLETED","sponsor":"Emory University","startDate":"2008-11","conditions":"Parenteral Nutrition","enrollment":100},{"nctId":"NCT01792830","phase":"PHASE3","title":"Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-10","conditions":"Poor Glycemic Control","enrollment":175},{"nctId":"NCT02036515","phase":"PHASE3","title":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-12","conditions":"Type 2 Diabetes Mellitus","enrollment":464},{"nctId":"NCT02706119","phase":"PHASE4","title":"Insulin in Total Parenteral Nutrition","status":"COMPLETED","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2016-07-01","conditions":"Diabetes Mellitus","enrollment":163},{"nctId":"NCT02585778","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-10-23","conditions":"Hypercholesterolaemia","enrollment":517},{"nctId":"NCT02642159","phase":"PHASE4","title":"Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-03-15","conditions":"Dyslipidemia","enrollment":413},{"nctId":"NCT00127634","phase":"PHASE3","title":"Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-07","conditions":"Diabetes Mellitus, Type 1","enrollment":385},{"nctId":"NCT00437112","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-02","conditions":"Diabetes Mellitus, Type 2","enrollment":142},{"nctId":"NCT00356109","phase":"PHASE3","title":"Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-08","conditions":"Diabetes Mellitus, Type 1","enrollment":494},{"nctId":"NCT02843399","phase":"","title":"Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-08-15","conditions":"Diabetes Mellitus Type 2","enrollment":15498},{"nctId":"NCT02585674","phase":"PHASE3","title":"Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-12","conditions":"Type 2 Diabetes Mellitus","enrollment":151},{"nctId":"NCT02459938","phase":"PHASE1","title":"Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia","status":"COMPLETED","sponsor":"Zosano Pharma Corporation","startDate":"2015-01","conditions":"Hypoglycemia","enrollment":16},{"nctId":"NCT02216799","phase":"PHASE4","title":"Glargine Insulin vs.Continuous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN)","status":"COMPLETED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2013-03","conditions":"Diabetic Patients With Gastrointestinal Cancer Undergoing Surgery and Receiving Parenteral Nutrition","enrollment":61},{"nctId":"NCT01759823","phase":"PHASE2, PHASE3","title":"Bone Marrow Derived Stem Cell Transplantation in T2DM","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2012-12","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT01065298","phase":"","title":"Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus-2","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2009-11","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT02468713","phase":"PHASE4","title":"Effect on Blood Chemistry and Inflammatory Marker of Omega-3 Enriched Total Parenteral Nutrition","status":"COMPLETED","sponsor":"Chonbuk National University Hospital","startDate":"2015-01","conditions":"Healthy","enrollment":16},{"nctId":"NCT00635492","phase":"","title":"CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Type 2 Diabetes Mellitus","enrollment":2515},{"nctId":"NCT01445951","phase":"PHASE3","title":"Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2011-09","conditions":"Type 1 Diabetes Mellitus","enrollment":518},{"nctId":"NCT00308308","phase":"PHASE3","title":"Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2006-02","conditions":"Diabetes, Type I","enrollment":589},{"nctId":"NCT02171390","phase":"PHASE4","title":"Endothelial Dysfunction, Inflammation and Insulin Resistance in Congenital Hypogonadism and Effect of Testosteron Replacement Therapy","status":"COMPLETED","sponsor":"Gulhane School of Medicine","startDate":"2008-08","conditions":"Hypogonadotrophic Hypogonadism","enrollment":130},{"nctId":"NCT02035943","phase":"NA","title":"Tight Glycemic Control and Insulin Administration During Parenteral Nutrition","status":"COMPLETED","sponsor":"Policlinico Hospital","startDate":"2008-01","conditions":"Critical Ill Patient Undergone Parenteral Nutrition","enrollment":20},{"nctId":"NCT01016509","phase":"NA","title":"Tight Glycemic Control During Angioplasty Revascularization Reduces Coronary Stent Restenosis","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2009-12","conditions":"Restenosis, Tight Glycemic Control","enrollment":200},{"nctId":"NCT00447213","phase":"PHASE2, PHASE3","title":"A Study for Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-04","conditions":"Diabetes Mellitus, Type 1","enrollment":70},{"nctId":"NCT00063128","phase":"PHASE2","title":"Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-04","conditions":"Diabetes Mellitus, Type 1","enrollment":119},{"nctId":"NCT00005889","phase":"NA","title":"Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion","status":"UNKNOWN","sponsor":"National Center for Research Resources (NCRR)","startDate":"1999-10","conditions":"Infant, Low Birth Weight, Hyperglycemia","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Parenteral Insulin","genericName":"Parenteral Insulin","companyName":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","companyId":"national-institute-of-diabetes-and-digestive-and-kidney-diseases-niddk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Parenteral insulin replaces or supplements the body's own insulin to regulate blood glucose by promoting glucose uptake into cells and storage as glycogen. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when oral agents are insufficient).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}